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Abstract
Pediatric populations continue to be understudied in clinical drug trials despite the increasing use of
pharmacotherapy in children, particularly with psychotropic drugs. Most pertinent to the clinical selection of drug
interventions are trials directly comparing drugs against other drugs. The aim was to measure the prevalence of
active drug comparators in neuropsychiatric drug trials in children and identify the effects of funding source on
comparator selection. We analyzed the selection of drugs and drug comparisons in clinical trials registered between
January 2006 and May 2012. Completed and ongoing interventional trials examining treatments for six
neuropsychiatric conditions in children were included. Networks of drug comparisons for each condition were
constructed using information about the trial study arms. Of 421 eligible trial registrations, 228 (63,699 participants)
were drug trials addressing ADHD (106 trials), autism spectrum disorders (47), unipolar depression (16), seizure
disorders (38), migraines and other headaches (15), or schizophrenia (11). Active drug comparators were used in
only 11.0% of drug trials while 44.7% used a placebo control and 44.3% no drug or placebo comparator. Even
among conditions with well-established pharmacotherapeutic options, almost all drug interventions were compared to
a placebo. Active comparisons were more common among trials without industry funding (17% vs. 8%, p=0.04).
Trials with industry funding differed from non-industry trials in terms of the drugs studied and the comparators
selected. For 73% (61/84) of drugs and 90% (19/21) of unique comparisons, trials were funded exclusively by either
industry or non-industry. We found that industry and non-industry differed when choosing comparators and active
drug comparators were rare for both groups. This gap in pediatric research activity limits the evidence available to
clinicians treating children and suggests a need to reassess the design and funding of pediatric trials in order to
optimize the information derived from pediatric participation in clinical trials.
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Introduction
Pediatric populations continue to be understudied in clinical
drug trials despite national and global initiatives to increase the
pediatric evidence guiding clinical practice[1-4]. In contrast,
there is increasing use of pharmacotherapy in children,
particularly with psychotropic drugs[5-8]. Antipsychotic and
antidepressant use in the United States, for example, more
than doubled from 8.6 to 39.4 per 1000 children and from 9.4 to
21.3 per 1000 children, respectively, over a ten year period
beginning in the mid-nineties[9,10]. However, the number of
trials supporting use of these and other psychotropic
medications in children is small, resulting in widespread off-
label prescribing among children with neuropsychiatric
conditions that is often supported by no or inconclusive
evidence at best[9,11,12].
Most pertinent to doctors’ clinical selections of drug
interventions are trials directly assessing drugs against other
drugs – active comparisons of an interventional drug to an
active drug comparator[13-15]. These comparative
effectiveness studies are particularly important when multiple
drugs are already well established in clinical practice. For
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example, epilepsy is treated primarily with pharmacotherapy
and has seen a recent rapid rise in medication options with ten
anti-epileptic medications receiving market approval in the
United States since 2000. In contrast, conditions like autism
spectrum disorders, which have little evidence for medication
effectiveness, may require placebo controlled trials to identify
the first efficacious drugs[16]. Placebo-controlled trials also
play an important role in studying conditions with known
placebo effects or with uncertainty around the efficacy of
existing drugs[17,18].
Nonetheless, analyses have shown that placebo-controlled
trials and trials without comparators are more likely to yield
results favoring the agent under investigation, potentially
making treatments appear more effective than they really
are[19-21]. Funding source may also play a role, with industry
funded trials more likely to avoid active comparators[21-23].
The aims of the study were to measure the prevalence of
active drug comparators in neuropsychiatric drug trials in
children and identify the effects of funding source on
comparator selection. We hypothesized that active
comparators would be used less frequently in industry funded
trials than in non-industry funded trials.
Methods
Trial selection
We identified eligible clinical trials using ClinicalTrials.gov, a
publicly available, web-based trial registry[24]. For each study,
standard information is provided that includes the condition and
interventions studied, the study phase and endpoints,
characteristics of the subjects enrolled, anticipated number of
subjects, funding sources supporting the trial, and current trial
status. We selected all trials that were pediatric, studied one or
more interventions for the treatment of a neuropsychiatric
condition, and started on or after January 1, 2006. All data
were downloaded from the registry on May 2, 2012. Pediatric
trials were defined as trials in which the mid-point of the age
range of enrolled subjects was less than 18 years[1]. We
defined drug trials as those studying an agent listed in the
WHO Anatomical Therapeutic Chemical classification
system[25].
Trials were categorized as entirely industry-funded, partially
industry-funded, or receiving no industry funding based on
sponsor information provided in the registry. Any trial labeled
as having an industry sponsor and no other was defined as an
entirely industry-funded trial, and partially industry-funded trials
were those labeled with an industry sponsor and at least one
other type of sponsor. All other combinations were defined as
non-industry trials. Trials that were withdrawn or terminated
prior to completion were excluded.
Among the remaining trials, those studying the six
neuropsychiatric conditions with the largest number of drug
trials were included: attention deficit hyperactivity disorder
(ADHD), autism spectrum disorders, unipolar depression,
seizure disorders, migraines and other headaches, and
schizophrenia (Figure 1). The five other conditions identified in
the set had too few registered drug trials to enable meaningful
analysis and these trials were excluded.
Network Construction
For each trial, we extracted information on the interventions
and study arms and identified the experimental and comparator
treatments. All eligible trials contributed to the structure of
condition-specific networks in which nodes represent
interventions and connections represent direct comparisons
between interventions[16,22,26,27]. Comparators were
classified as active if the trial registration listed another specific
therapeutic intervention, as a placebo if a placebo (or
synonym) was described, or a control otherwise. Crossover
studies with a placebo control arm were categorized as
placebo-controlled trials. Trials involving different doses of a
single drug without another active or placebo comparator were
included in the networks as single arm trials. Multiple-arm trials
with a placebo and at least one active comparator were
classified as active comparator trials.
Since trials were used as the denominator in the networks,
three trials with more complicated designs could not be
completely coded. In these cases, the first comparison listed in
the trial record was included in the network.
Analysis
Analysis of the networks was based on three metrics that
quantify biases in the distribution of interventions and their
comparisons. Each of the network metrics is considered
relative to a standard baseline, which normalizes for
differences in size and density, and suggests levels of
significance for the metrics[28]. The size and density of a
network represents how many interventions were considered
for the conditions, and how frequently those interventions are
tested against the other interventions.
Degree centralization indicates whether some treatments are
chosen as comparators more often than others[29]. Degree
centralization increases from zero to one as the network
approaches a star-shaped pattern, where one intervention is
the preferred comparator in every study. The degree
centralization percentile is calculated using a baseline of
network permutations with the same size and density as the
observed network. The simulated networks represent networks
in which there is no underlying bias in comparator selection,
and thus reflects the extremity of the observed centralization
score[28,30].
The probability of interspecific encounter (PIE) measures the
diversity of a treatment and is calculated as the probability that
any two randomly selected treatment groups in the network are
treated with two different interventions[16,31,32]. PIE scores
increase as trials are distributed more evenly across a large
number of treatments. Conversely, trials with smaller numbers
of treatments and in which certain interventions are studied
more often than others will have a lower PIE score. Scores
between 0.7 and 0.8 represent poor diversity, and scores lower
than 0.7 represent very low diversity with a strong preference
for specific treatments. The PIE’ is the raw PIE score
normalized by the maximum possible PIE score for the number
of trials in the network.
The role of funding in the networks was analyzed in terms of
funding exclusivity, which measures the separation of funding
across the set of drugs examined in each condition. For each
Comparators in Neuropsychiatric Trials of Children
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drug, if every trial is conducted with only industry funding, or
only non-industry funding, then that drug is considered to be
funded exclusively by one funding type. The funding exclusivity
is then defined as the proportion of all drugs across a condition
funded exclusively by one funding type (either industry or non-
industry but not both). As with the other measures, funding
exclusivity is considered relative to a simulated baseline of
permutations, which indicates the extremity of the score
beyond what random chance is expected to produce.
Results
Drugs were studied in 228 trials, corresponding to 54.2% of
421 trials meeting the inclusion criteria and conditions (see
Table S2 for trials and Figures S1 to S6 for details of trials
examining interventions other than drugs). Of the 228, 11.0%
(25/228) employed an active drug comparator, representing the
overall number of active comparator trials. Another 44.7%
(102/228) used a placebo control and 44.3% (101/228) were
single-group assignments or trials comparing drugs with
behavioral or other non-drug interventions (Figure 2).
Drug Trial Characteristics
Study characteristics are presented in Table 1. The total
number of anticipated or actual enrolments across the 228
trials was 63,699. The median enrolment in trials was low,
ranging from 59.5 for seizure disorders, to 201 for
schizophrenia. Fewer than 10 different drug interventions were
studied for unipolar depression and schizophrenia. For ADHD,
unipolar depression, migraines and other headaches, and
schizophrenia, 20% or more of trials focused on a single drug.
Figure 1.  Neuropsychiatric interventional studies involving children, registered on clinicaltrials.gov January 2006 to May
2012.  The set of pediatric interventional studies registered on ClinicalTrials.gov that met the inclusion criteria and included at least
one drug intervention (blue); or only non-drug interventions (grey). Abbreviations: ADHD: attention deficit hyperactivity disorder;
ASD: autism spectrum disorder.
doi: 10.1371/journal.pone.0084951.g001
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Figure 2.  Selection and classification of clinical drug trials.  The trial selection and classification used in the analyses are also
classified by funding type.
doi: 10.1371/journal.pone.0084951.g002
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Drug treatment networks are illustrated for the six conditions
(Figures 3 to 8). Among the drug trials, the predominant source
of funding was industry, with as many as 88% of unipolar
depression trials and 82% of schizophrenia trials funded
exclusively by industry. Autism spectrum disorders represented
the only condition in which the majority of trials (53%) were
funded without industry sponsors.
Comparators and Treatment Networks for Drug Trials
Less than 10% of drug trials employed an active comparator
among trials examining autism spectrum disorders, seizure
disorders, and schizophrenia (Table 2). The majority of drug
trials for autism spectrum disorders and migraines and other
headaches employed a placebo comparator, while most trials
Table 1. Characteristics of pediatric drug trials registered in ClinicalTrials.gov for selected conditions.
 
Attention Deficit
Hyperactivity Disorder
Autism Spectrum
Disorders Seizure DisordersUnipolar Depression
Migraines and
Headaches Schizophrenia
Drug trials, No. 106 47 38 16 15 11
Total enrolment (median)a 18385 (135) 3690 (60) 4231 (59.5) 3251 (160) 7390 (150) 2385 (201)
Phase III/IV trials, No. (%)b 87/101 (86%) 24/43 (56%) 24/36 (67%) 10/15 (67%) 10/12 (83%) 11/11 (100%)
Trials with safety outcomes, No. (%)c 60 (57%) 29 (62%) 20 (53%) 7 (44%) 6 (40%) 6 (54%)
Unique drug interventions, No. 22 25 22 9 12 6
Most common drug tested methylphenidate aripiprazole levetiracetam desvenlafaxine rizatriptan aripiprazole
-No. (%) 41 (39%) 8 (17%) 7 (18%) 6 (38%) 3 (20%) 4 (36%)
Funding source       
-Entirely industry-funded, No. (%) 57 (54%) 12 (26%) 26 (68%) 14 (88%) 7 (47%) 9 (82%)
-Partially industry-funded, No. (%) 13 (12%) 10 (21%) 2 (5.3%) 1 (6.2%) 1 (6.7%) 1 (9.1%)
-No industry funding, No. (%) 36 (34%) 25 (53%) 10 (26%) 1 (6.2%) 7 (47%) 1 (9.1%)
a Median enrolment is from expected enrolment for trials in the recruiting phase and actual enrolment for completed trials.
b Not all trials specified information about the clinical trial phase; the denominator is the number of trials with this information registered.
c Trials for which the registration included one or more measurable outcomes labelled as a safety outcome.
doi: 10.1371/journal.pone.0084951.t001
Figure 3.  The drug treatment network for ADHD, indicating funding source.  The network of drug treatments for 106 ADHD
trials, where the areas of circles are proportional to the total number of trials examining the treatments, and the thickness of the lines
are proportional to the number of active comparisons between drugs or with placebo. Black represents industry-funded trials; grey
represents trials partially funded by industry; and blue represents non-industry funding. The numerical labels are the number of trials
in each group, matching the colors.
doi: 10.1371/journal.pone.0084951.g003
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for unipolar depression, seizure disorders, and schizophrenia
were single group studies.
All six conditions featured strong indications of lack of
diversity and high centralization, reflecting a tendency for trials
to focus on select drugs and to preferentially choose certain
comparators while avoiding others (Table 2). This was most
pronounced for autism spectrum disorder trials, which formed a
perfectly star-shaped network with every drug compared to a
placebo or without a control (Figure 4). Seizure disorder trials
were similar (Figure 5), with all but two of the trials comparing a
drug intervention to a placebo or no control. While ADHD trials
had a relatively higher proportion of active comparator trials,
the treatment network also demonstrated low diversity and high
centralization because of a tendency for trials to focus on a
limited number of drugs and to preferentially select one of a
few drug comparators (Figure 3).
Role of Funding on Drug and Comparator Selection
Industry and non-industry funded trials differed in terms of
the drugs studied and the comparators employed in trials
(Table 3). Drugs were generally studied exclusively by industry
or non-industry sources, with 73% (61/84) of drugs studied only
by either industry or non-industry sponsors (see Table S1).
Unipolar depression included the highest proportion of drugs
examined only by industry (78%; 7/9) and migraines and other
headaches the highest proportion examined only by non-
industry (67%; 8/12). High levels of funding exclusivity were
evident relative to a random baseline in all conditions except
unipolar depression (which was dominated by industry-funded
trials allowing for only two unique funding exclusivity scores).
Amongst the other five conditions, four were found to have
funding exclusivity percentiles above 97% when compared to
the permutation baseline, indicating a strong presence of bias.
Fewer than half (12/25) of the active comparator trials
received industry funding. Overall, trials with industry funding
were less likely to use active drug comparators compared to
trials funded by non-industry sources (8.0% [12/152] vs. 17.1%
[13/76], p-value for chi-square = 0.04). Among active
comparator trials, 90% (19/21) of the unique active
comparisons were funded exclusively by industry or non-
industry funders. The treatment network for ADHD
demonstrated the most even distribution of funding among
active comparator trials, although industry remained less likely
to use active comparators compared to non-industry sources
(11% of industry-funded trials vs. 22% of non-industry-funded
trials).
Figure 4.  The drug treatment network for autism spectrum disorders, indicating funding source.  The network of drug
treatments for 47 autism spectrum disorder trials, where the areas of circles are proportional to the total number of trials examining
the treatments, and the thickness of the lines are proportional to the number of active comparisons between drugs or with placebo.
Black represents industry-funded trials; grey represents trials partially funded by industry; and blue represents non-industry funding.
The numerical labels are the number of trials in each group, matching the colors.
doi: 10.1371/journal.pone.0084951.g004
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Figure 5.  The drug treatment network for seizure disorders, indicating funding source.  The network of drug treatments for
38 seizure disorder trials, where the areas of circles are proportional to the total number of trials examining the treatments, and the
thickness of the lines are proportional to the number of active comparisons between drugs or with placebo. Black represents
industry-funded trials; grey represents trials partially funded by industry; and blue represents non-industry funding. The numerical
labels are the number of trials in each group, matching the colors.
doi: 10.1371/journal.pone.0084951.g005
Figure 6.  The drug treatment network for unipolar depression, indicating funding source.  The network of drug treatments for
16 unipolar depression trials, where the areas of circles are proportional to the total number of trials examining the treatments, and
the thickness of the lines are proportional to the number of active comparisons between drugs or with placebo. Black represents
industry-funded trials; grey represents trials partially funded by industry; and blue represents non-industry funding. The numerical
labels are the number of trials in each group, matching the colors.
doi: 10.1371/journal.pone.0084951.g006
Comparators in Neuropsychiatric Trials of Children
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Discussion
Active comparator trials in pediatric drug research remain
limited across a number of neuropsychiatric conditions and
drug trials funded by industry are less likely to involve active
drug comparisons than their non-industry counterparts. This is
most pronounced in conditions that have few known
pharmaceutical treatments, but is also the standard for
diseases treated primarily with medications in which clinicians
already have a number of well-established drug options. We
also found substantial differences between the drugs and
comparators chosen by industry and non-industry groups,
showing strong preferences for studying specific drugs and
drug comparisons.
Prior work has demonstrated concerning findings with
respect to the medical evidence guiding the clinical care of
children. First, there appears to be a paucity of clinical research
—and particularly randomized controlled trials—conducted in
pediatric relative to adult patients[1,33-35]. This pattern exists
across a number of disease conditions and has been attributed
chiefly to the smaller disease burden among children as well as
issues around the cost and complexity of conducting research
in children, all of which translate into a lower potential for
profitability[36-38]. Second, the research that is conducted in
children appears to be of only moderate quality with pediatric
studies demonstrating high risks of bias in study design and
outcome reporting and insufficient safety
assessments[12,30,39,40]. The current study adds to this body
of findings by demonstrating a gap in the pediatric research
portfolio, specifically with respect to selection of study drugs
and drug comparisons.
There are a number of scenarios that necessitate placebo-
controlled trials, such as conditions with limited pharmaceutical
options, or where there is uncertainty regarding the true
efficacy of standard options compared to placebo[41-43].
However, these arguments do not fully explain our findings that
pediatric drug trials are conducted predominantly with placebos
or no controls in the study of ADHD, seizure disorders, unipolar
depression, schizophrenia, and migraines and other
headaches. In each of these conditions, less than a quarter of
the trials were active comparator trials. Although it is difficult to
estimate what the appropriate rate of active-comparator trials
should be, examining the number of condition-specific drugs
that have Federal Drug Agency (FDA) approval in the United
States provides a gauge of the existing availability and
establishment of drug options. For example, among the
antiepileptic drugs we examined, 57% are FDA approved for
seizure management, indicating that for the majority of drugs,
their superiority to placebo have been previously established
with reasonable certainty. Similarly, for ADHD, unipolar
depression, migraines and other headaches, and
schizophrenia, the rates of FDA approval for the studied drugs
indicate that there are a number of well-established existing
drug options (30%, 60%, 42%, and 83%, respectively). Even
Figure 7.  The drug treatment network for migraines and other headaches, indicating funding source.  The network of drug
treatments for 15 migraines and other headaches trials, where the areas of circles are proportional to the total number of trials
examining the treatments, and the thickness of the lines are proportional to the number of active comparisons between drugs or with
placebo. Black represents industry-funded trials; grey represents trials partially funded by industry; and blue represents non-industry
funding. The numerical labels are the number of trials in each group, matching the colors.
doi: 10.1371/journal.pone.0084951.g007
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given the potential benefit of including placebo trials within the
research portfolio for a condition, one would expect a greater
proportion of active-comparator trials based on the amount of
existing evidence supporting the efficacy of available drugs.
Figure 8.  The drug treatment network for schizophrenia, indicating funding source.  The network of drug treatments for 11
schizophrenia trials, where the areas of circles are proportional to the total number of trials examining the treatments, and the
thickness of the lines are proportional to the number of active comparisons between drugs or with placebo. Black represents
industry-funded trials; grey represents trials partially funded by industry; and blue represents non-industry funding. The numerical
labels are the number of trials in each group, matching the colors.
doi: 10.1371/journal.pone.0084951.g008
Table 2. Network metrics associated with the drug-based comparative effectiveness networks.
 ADHD
Autism Spectrum
Disorders Seizure DisordersUnipolar Depression
Migraines and
Headaches Schizophrenia
Number of included drug trials 106 47 38 16 15 11
Number of drug trials involving an active drug
comparator (%) 16 (15%) 0 (0%) 2 (5.3%) 3 (19%) 3 (20%) 1 (9.1%)
Network size (drugs with active and placebo
comparisons) 23 26 23 10 13 7
Density of the network 0.15 0.08 0.07 0.13 0.15 0.18
Raw degree centralization 0.56 0.71 0.43 0.36 0.45 0.38
Degree centralization percentilea ≈100% =100% ≈100% 87% 99% 60%
Probability of interspecific encounter (PIE) 0.81 0.74 0.81 0.88 0.87 0.82
Normalised PIE (PIE’) 0.84 0.76 0.81 0.90 0.90 0.82
a The percentile is equal to 100% when the degree centralization is known to be uniquely high, and approximately 100% when after 100,000 simulated networks, no higher
value was encountered amongst the random baseline set of networks.
doi: 10.1371/journal.pone.0084951.t002
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We found that industry-funded trials were less likely to
choose active comparators in their trials compared to non-
industry studies, and that they focused on drugs and drug
comparisons that were different than their non-industry
counterparts. This type of bias in the selection and avoidance
of specific drugs and drug comparisons by manufacturers has
been previously described for antirheumatic drugs,
antipsychotics, and anti-fungal agents[22,44,45]. Drug
companies focus primarily on the drugs that they manufacture,
which tend to be newer and more expensive agents[44,46].
When comparators are employed, they may choose inactive or
placebo controls as they are most likely to yield favorable
results that can be readily used for marketing purposes[47].
Alternatively, specific comparators may be favored because
they are considered suboptimal, again ensuring favorable
results for the drug under study. It is likely that regulatory
agencies have contributed to the preponderance of placebo-
controlled trials since active-comparator trials are not required
as part of the drug approval process[14,47]. However, it has
also been suggested that the choice of comparators by industry
sponsors represents calculated marketing decisions to
augment drug effectiveness estimates and promote the agents
under study[22,44,46]. Unfortunately, this type of biased
comparator selection limits the breadth of evidence available
on the true value of a drug in the context of all available
options.
Our study is limited to the data available in the registry and
we were unable to verify the completeness or accuracy of the
data provided. However, ClinicalTrials.gov is the largest and
most widely used trial registry and performs internal data
quality and verification procedures prior to posting the
information submitted by investigators. It is also unlikely that
unregistered trials systematically included a higher rate of
active comparisons or studied drugs that were
underrepresented in the current research networks.
Conclusions
In this study across six neuropsychiatric conditions in
children, we found a dearth of trials examining the comparative
effectiveness of drugs, and high proportions of trials designed
with either no control or a placebo. This was apparent across
the funding spectrum, but more pronounced among trials with
industry funding. The lack of active comparisons spanned most
neuropsychiatric conditions and was evident both for conditions
in which drug therapy remains exploratory (e.g. autism), and for
those in which drugs are well-established as the primary
treatment and are in widespread clinical use (e.g. seizure
disorders). The interventions and comparators examined by
industry and non-industry funding sources were mostly distinct,
suggesting that the evidence base for many approved
treatments is derived exclusively by specific types of sponsors.
The overall bias against comparative effectiveness trials and
the strong funding exclusivity between industry and non-
industry funded drugs and drug comparisons may limit the
reliability of emerging evidence for the treatment of children
with neuropsychiatric conditions, despite the growing use of
pharmacotherapy in this area. The mechanisms underlying the
design and funding of pediatric trials should be reassessed in
Table 3. Funding characteristics of drug-based clinical trials.
 ADHD (n=106)
Autism Spectrum
Disorders (n=47)
Seizure Disorders
(n=38)
Unipolar Depression
(n=16)
Migraines and
Headaches (n=15) Schizophrenia (n=11)
Trials employing an active drug
comparator, No. (%) 16 (15%) 0 2 (5.3%) 3 (19%) 3 (20%) 1 (9.1%)
- Entirely industry-funded 7 (6.6%) 0 0 3 (19%) 0 1 (9.1%)
- Partially industry-funding 1 (0.9%) 0 0 0 0 0
- No industry funding 8 (7.5%) 0 2 (5.3%) 0 3 (20%) 0
Trials employing a placebo comparator
only, No. (%) 44 (42%) 31 (66%) 13 (34%) 4 (25%) 8 (53%) 3 (27%)
- Entirely industry-funded 29 (27%) 8 (17%) 9 (24%) 4 (25%) 5 (33%) 3 (27%)
- Partially industry-funding 4 (3.8%) 5 (11%) 1 (2.6%) 0 1 (6.7%) 0
- No industry funding 11 (10%) 18 (38%) 3 (7.9%) 0 2 (13%) 0
Single group and other drug trials with no
placebo or active drug comparator, No.
(%)a
46 (43%) 16 (34%) 23 (61%) 9 (56%) 4 (27%) 7 (64%)
- Entirely industry-funded 21 (20%) 4 (8.5%) 17 (45%) 7 (44%) 2 (13%) 5 (45%)
- Partially industry-funding 8 (7.6%) 5 (11%) 1 (2.6%) 1 (6.2%) 0 1 (9.1%)
- No industry funding 17 (16%) 7 (15%) 5 (13%) 1 (6.2%) 2 (13%) 1 (9.1%)
Funding exclusivity for drugs, (%)b 73% (16/22) 71% (17/25) 68% (7/9) 78% (7/9) 92% (11/12) 83% (5/6)
Funding exclusivity for active comparisons,
(%)b 85% (11/13) NA (0/0) 100% (2/2) 100% (2/2) 100% (3/3) 100% (1/1)
a Includes trials comparing drugs with behavioral or other non-drug interventions.
b Funding exclusivity represents the percentage of drugs and active comparisons whose constituent trials are funded exclusively by industry or by non-industry sources.
doi: 10.1371/journal.pone.0084951.t003
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order to optimize the information derived from pediatric
participation in clinical trials.
Supporting Information
Table S1.  Drugs examined in neuropsychiatric trials
involving children, across six conditions, ordered by
prevalence in the set of 228 trials.
(DOC)
Table S2.  The set of included trials for each of the six
conditions.
(DOC)
Figure S1.  The treatment network for ADHD including
interventions other than drugs. There were 162 trials that
met the inclusion criteria for ADHD, illustrated here as a
treatment network (inclusive of non-drug trials). Black circles
represent drug trials, grey nodes represent non-drug trials. The
area of the circles is proportional to the number of trials.
Connections represent comparisons in trials. Connection width
is proportional to the number of trials in which the comparison
was present. The numbers for both circles and connections
indicate trial counts.
(TIF)
Figure S2.  The treatment network for autism spectrum
disorders including interventions other than drugs There
were 116 trials that met the inclusion criteria for autism
spectrum disorders, illustrated here as a treatment network
(inclusive of non-drug trials). Black circles represent drug trials,
grey nodes represent non-drug trials. The area of the circles is
proportional to the number of trials. Connections represent
comparisons in trials. Connection width is proportional to the
number of trials in which the comparison was present. The
numbers for both circles and connections indicate trial counts.
(TIF)
Figure S3.  The treatment for seizure disorders including
interventions other than drugs There were 49 trials that met
the inclusion criteria for seizure disorders, illustrated here as a
treatment network (inclusive of non-drug trials). Black circles
represent drug trials, grey nodes represent non-drug trials. The
area of the circles is proportional to the number of trials.
Connections represent comparisons in trials. Connection width
is proportional to the number of trials in which the comparison
was present. The numbers for both circles and connections
indicate trial counts.
(TIF)
Figure S4.  The treatment network for unipolar depression
including interventions other than drugs. There were 66
trials that met the inclusion criteria for unipolar depression,
illustrated here as a treatment network (inclusive of non-drug
trials). Black circles represent drug trials, grey nodes represent
non-drug trials. The area of the circles is proportional to the
number of trials. Connections represent comparisons in trials.
Connection width is proportional to the number of trials in which
the comparison was present. The numbers for both circles and
connections indicate trial counts.
(TIF)
Figure S5.  The treatment network for migraines and other
headaches including interventions other than drugs. There
were 24 trials that met the inclusion criteria for migraines and
other headaches, illustrated here as a treatment network
(inclusive of non-drug trials). Black circles represent drug trials,
grey nodes represent non-drug trials. The area of the circles is
proportional to the number of trials. Connections represent
comparisons in trials. Connection width is proportional to the
number of trials in which the comparison was present. The
numbers for both circles and connections indicate trial counts.
(TIF)
Figure S6.  The treatment network for schizophrenia
including interventions other than drugs. There were 24
trials that met the inclusion criteria for schizophrenia, illustrated
here as a treatment network (inclusive of non-drug trials). Black
circles represent drug trials, grey nodes represent non-drug
trials. The area of the circles is proportional to the number of
trials. Connections represent comparisons in trials and the
width represents the number of trials in which the comparison
was present. The numbers for both circles and connections are
the number of trials.
(TIF)
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